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| INTRODUC TI ON
Irritable bowel syndrome (IBS) is a brain-gut disorder characterized by a chronic relapsing-remitting nature of symptoms, including abdominal pain and altered bowel habits. Global prevalence, based predominantly on the Rome III criteria, is estimated at 5%-20%, 1 with varying rates according to geographical area and diagnostic criteria used. 2 Recent studies using the more restrictive Rome IV criteria point to lower prevalence rates of 5%-6%. 3, 4 Although the exact pathophysiology of IBS remains incompletely understood, a multifactorial origin is generally recognized, in which dysregulation of the brain-gut axis has a central role. Other factors include aberrant neuroimmune interactions, visceral hypersensitivity, genetic susceptibility, microbiome alterations, and psychosocial factors. 5, 6 As interference of IBS with patients' everyday lives is extensive 7 and treatment results are often unsatisfactory, quality of life is low and comparable to chronic somatic diseases. 8 Given the heterogeneous nature of the disorder, symptom patterns vary widely both between and within IBS patients and predicting individual disease courses remains challenging. IBS is known as a chronic, in many patients lifelong, condition with fluctuating gastrointestinal (GI) symptoms. Symptoms such as abdominal pain, constipation, and diarrhea are known to occur in episodes of several days followed by days without symptoms. 9 In addition, transitions from one predominant bowel habit type to the other are common and occur in up to 75% of patients. [10] [11] [12] Quality of life, on the other hand, has been shown to be relatively stable over a 3-month period. 13 With regard to long-term symptom variability, several studies have investigated the disease course of IBS and have shown varying results with respect to symptom severity and quality of life. The majority of the prospective studies had a follow-up period of approximately 1 year, which is relatively short for a condition such as IBS. In addition, there is a lack of follow-up data for the Dutch population.
As implications of IBS on quality of life have shown to vary considerably between different countries, 14 it is of added value to expand earlier findings and investigate the natural history of IBS in a Dutch, well-characterized population.
Finally, as IBS is a symptom-based diagnosis, it is of interest to assess how symptoms evolve over time and how these symptoms and long-term quality of life relate to the Rome diagnostic criteria for IBS, in particular when they are confirmed in a telephonic interview rather than a purely survey-based assessment at follow-up measurements.
Hence, the current follow-up study, which is part of a large prospective cohort study on the pheno-and genotypical characterization of IBS in the Netherlands, aimed (a) to gain further insight into symptom evolution and long-term quality of life over a 5-year follow-up period; (b) to identify baseline predictors for higher symptom severity and greater quality of life impairment at followup; and (c) to assess how point a and b differ between patients that remain Rome III-positive and those who are Rome III-negative at follow-up. Helsinki. 18 The study had been registered in the US National Library of Medicine (NCT00775060). All subjects gave a written informed consent prior to participation.
| MATERIAL S AND ME THODS

| Irritable bowel syndrome cohort study
| Subjects
Patients were assigned IBS subtypes based on their reported pre- Approximately 5 years (±2 year) after inclusion, patients were invited to complete several follow-up questionnaires. These included the same questionnaires that were filled out at baseline (with the exception of the end-of-day diary), with the addition of other questionnaires to further standardize the phenotyping of our population and to allow valid comparisons to other cohorts (ie, international harmonization). Additional questionnaires included the following:
| Data collection
the GSRS specific for IBS (GSRS-IBS, scale 1-7, generates symptom scores for the following subdomains: abdominal pain, bloating, constipation, diarrhea, and satiety) 24 ; the Visceral Sensitivity Index (VSI, scale 1-6, assesses GI-specific anxiety or, in other words, fear for GI symptoms) 25 ; and the Satisfaction With Life Scale (SWLS, scale 1-6, assesses individual overall satisfaction with life). [26] [27] [28] As it is known that IBS can affect the ability to work, 29 a self-report questionnaire regarding productivity (Productivity Cost Questionnaire (PCQ), validated for the Dutch situation) was included as well. 30, 31 Patients could opt for paper or digital web-based (invitation was sent via email) questionnaires to encourage participation. One reminder was sent when no response had been received within 1 month. A trained clinical investigator contacted all patients who did respond and confirmed the Rome III diagnostic criteria during a telephonic interview with them. Patients were reassigned IBS subtypes based on their predominant bowel habit, during the follow-up measurement.
Reliable information on treatment history was not available for the majority of patients as this was not registered systematically during the follow-up period. Furthermore, many patients underwent selftreatment or treatment via their primary care physician, of which data were not available and were therefore not included in the analysis of the current study.
| Statistical analysis
All statistical analyses were carried out using IBM SPSS statis- continuous data between subgroups, Mann-Whitney U tests were used. Wilcoxon-signed-rank tests were used to evaluate differences within subjects over time. For categorical data, groups were compared using the chi-square or Fisher's exact test and differences over time were evaluated using the McNemar's test.
Correlations were assessed according to Spearman. To decrease the false discovery error rate induced by multiple testing, a post hoc correction was applied using the Benjamini-Hochberg step-up procedure.
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The patients participating in the follow-up were divided into two 
| Follow-up-demographics, clinical characteristics, and symptoms of the Rome IIIpositive and Rome III-negative patients
The 161 patients in whom IBS criteria could be checked by phone were included in the final analysis. The majority of patients was female (74.5%), and median age was 53 years old (IQR = 36-65).
In total, 49 out of the 161 (30.4%) did no longer fulfill the Rome III criteria for IBS at follow-up ( Figure 1 ). Demographical and clinical characteristics at follow-up of the Rome III-negative and Rome III-positive patients are shown in Table 1 . The groups did not differ significantly in age or gender, although the Rome III-positive group was slightly younger. As expected, Rome III-negative patients had significantly lower GI symptom scores compared to Rome III-positive patients (assessed by both the GSRS and GSRS-IBS) at follow-up, which was shown on each of the following subdomains: abdominal pain, bloating, diarrhea, constipation, indigestion (all P < 0.001), and satiety (P < 0.005). Despite having less GI symptoms, they did not have significantly higher quality of life or more satisfaction with life.
Although Rome III-negative patients had significantly less GI-specific anxiety at follow-up (P < 0.001), they did not have less symptoms of general anxiety and depression. Moreover, levels of impaired work productivity and absence from work did not differ between both groups. Table 2 shows baseline demographics and clinical characteristics (at inclusion time into the cohort) of patients who were Rome IIIpositive and Rome III-negative at follow-up. With regard to baseline levels of GI symptom severity (assessed by the GSRS, as baseline GSRS-IBS data were not available), it can be noted that Rome IIInegative patients had slightly lower baseline scores for abdominal pain. Nevertheless, after correction for multiple comparisons, this did not reach statistical significance nor did other GI symptoms differ significantly between the groups at baseline. In terms of general anxiety, depression, and general quality of life scores, no baseline differences were observed between Rome III-positive and Rome III-negative patients (Table 2) . Moreover, the proportion of patients that had been recruited for the cohort from the primary care setting F I G U R E 1 Flowchart of follow-up of N = 379 IBS patients included in the Maastricht IBS cohort study. IBS, irritable bowel syndrome; N, number did not differ between Rome III-positive and Rome III-negative patients ( Table 2 ). In addition, the distribution in baseline IBS subtypes did not differ between Rome III-positive and Rome III-negative patients (Table 2) . Table 3 shows the evolution of clinical characteristics and symptoms over time by pairwise comparisons between baseline and follow-up measurements. Overall, improvements in GI symptom severity (assessed by the GSRS, as baseline GSRS-IBS data were not available), general quality of life, and general anxiety and depression over a 5-year period were small and did not reach significance in patients that still met the Rome III diagnostic criteria at follow-up. Symptom severity for abdominal pain, diarrhea, constipation, and indigestion did improve significantly over time in the Rome III-negative patients, although they still had "low to moderate" levels of symptoms after 5 years, with a median abdominal pain GSRS score of 2.33 (IQR = 1.33-3.00), and a median indigestion GSRS score of 2.88 (IQR = 2.25-3.94). However, similar to the Rome III-positive patients, the Rome III-negative patients did not
| Baseline-demographics, clinical characteristics, and symptoms of the Rome IIIpositive and Rome III-negative patients
| Symptom evolution over time
improve significantly in quality of life during the follow-up period. In addition, their comorbid depression scores were relatively unaltered.
With regard to IBS subtype based on predominant bowel habit, Figure S1 illustrates the proportion of IBS subtypes at baseline and at follow-up. Sixty-two (55.4%) out of 112 Rome III-positive patients had changed IBS subtype during the follow-up period.
In Figure S2 , the within-patient subtype changes from baseline to follow-up are shown. IBS-D appeared the most stable subtype (72.5% of Rome III-positive unchanged), whereas IBS-M and IBS-C were least stable (76.6% and 60.9% of Rome III-positive changed, respectively).
TA TA 
| D ISCUSS I ON
In the current prospective study, we evaluated the natural symptom evolution of patients with IBS in the Maastricht IBS cohort over time. 33 We demonstrated that 30.4% of patients did no longer fulfill the Rome III criteria after a 5-year follow-up period. The most salient finding is that quality of life did not improve significantly in patients who showed a decrease in gastrointestinal symptom severity (ie, being Rome III-negative at follow-up), compared to patients who had unaltered symptom severity over time (Rome III-positive). In addition, general well-being in terms of comorbid general anxiety and depression, work absenteeism and productivity, and life satisfaction were also comparable in those who still fulfilled the Rome III criteria at follow-up, when compared to those who did not.
Several studies have investigated IBS symptom evolution in relation to diagnostic criteria in patient cohorts, with varying results. A study by Williams et al using the Rome II criteria reported that 52% had no IBS 2 years after web-based diagnosis, 12 Ford et al found that 28% did not meet the Manning criteria after 10 years, 34 Mearin et al reported that abdominal pain frequency decreased in 26% after 1 year, 35 Note: Numbers may not add up to total due to missing. Please note that several variables shown in Table 1 derive from questionnaires not administered at baseline and could therefore not be considered in the comparison of baseline variables in Table 2 . Rather unexpectedly, we found that a decrease in GI symptom severity did not lead to an improved quality of life in our study.
Clevers et al recently evaluated longitudinal symptom changes over
time and, in contrast to our results, found that patients with lower GI symptom severity had significantly higher quality of life scores. 37 They also demonstrated that GI-specific anxiety is associated with an increase in GI symptom severity, which is in agreement with our results as GI-specific anxiety was significantly lower in the group that did not fulfill the Rome III criteria. The inconsistency between our data in terms of quality of life might be explained in part by the different questionnaires used. Clevers et al used an IBS-specific questionnaire, the IBS-QoL, 38 which assesses more disease-specific Numbers may not add up to total due to missing. Abbreviations: BMI, body mass index (kg m −2 ); GSRS, gastrointestinal symptom rating scale; HADS, hospital anxiety and depression scale; IBS, Irritable bowel syndrome; IQR, interquartile Range; MCS, mental quality of life composite summary as assessed by SF-36. N, number of patients included in the analysis; PCS, physical quality of life composite summary as assessed by SF-36. ***P < 0.001 vs baseline; **P < 0.005 vs baseline; *P < 0.01 vs baseline; ∞ P < 0.05 vs baseline.
changes in quality of life in contrast to generic quality of life instruments, such as the SF-36 that we used. Our data can therefore also be compared with other diseases and with the general population.
Both the Rome III-positive and Rome III-negative group showed lower mean quality of life than the mean of a Dutch population sample 39 and of a US-based population without a functional GI disorder. 40 Additionally, we used the validated SWLS to score overall life satisfaction. This has been used in healthy persons and in patients with Crohn's disease, 41 but, to our knowledge, not in patients with IBS. We found scores comparable to the ones reported by Crohn's disease patients for both the Rome III-positive and Rome III-negative group.
In contrast to GI symptom severity, we found that quality of life did not improve over time in those that were Rome III-negative at Internet-delivered exposure-based CBT, 50 and home-based CBT. 51 In that light, it will be interesting to explore whether these developments can affect long-term quality of life and well-being in patients with IBS.
Several limitations of the current study should be noted. Only two time-points within the 5-year period were assessed; no further data were available about the period in between the baseline and follow-up measurement, including data on treatment received in this period. Therefore, we can neither comment about the frequency and duration of IBS flares within these 5 years, nor about the effect of treatment on symptoms, nor on the causal order of the impaired quality of life and psychological comorbidities. Moreover, selection bias cannot be excluded. Follow-up cohort studies depend on long-term dedication of their participants, and the proportion of non-responders (loss to follow) in this study was 46.4%. To assess
potential selection bias, we tested for differences in baseline characteristics between responders and non-responders at follow-up.
The groups did not differ in baseline demographic and lifestyle characteristics, nor in baseline symptom scores and subtypes (data not shown 2 In contrast to earlier studies on follow-up of IBS, our study method implied a complete reevaluation of the diagnosis in a telephonic interview and, thus, allows for a more valid and less biased interpretation of Rome-diagnosed IBS prevalence over time.
In conclusion, the current prospective study contributes to existing insight regarding symptom evolution over time in patients with IBS and showed that 30% of patients did no longer fulfill the Rome III criteria after a 5-year follow-up period. However, the decrease in GI symptom severity (ie, being Rome III-negative at follow-up) did not impact quality of life nor life satisfaction. Our results indicate that long-term quality of life and general well-being might depend on comorbid psychological symptoms, that is, affective states, rather than gastrointestinal symptom severity.
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